Prelude Capital Management’s BioPlus Acquisition Corp. Unit BIOSU Stock Holding History

Prelude Capital Management’s Portfolio BIOSU Stock Details BIOSU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-25,000	Closed	-$251K	–	1747
2022 Q3	$251K	Hold	25,000	–	–	0.01%	958
2022 Q2	$252K	Hold	25,000	–	–	0.01%	1156
2022 Q1	$250K	Hold	25,000	–	–	0.01%	1155
2021 Q4	$250K	Buy	+25,000	New	+$250K	0.01%	1437

Other funds holding BIOSU

HIM

HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

BCL

Bracebridge Capital LLC Boston, Massachusetts $5.53B AUM 25.79% 1-Year Est. Return

Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

LCM

Landscape Capital Management Englewood, New Jersey $1.54B AUM 30.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Prelude Capital Management's BIOSU Position: Q4 2022 in Review

Prelude Capital Management sold out of BioPlus Acquisition Corp. Unit (BIOSU) in Q4 2022, closing a stake of 25,000 shares — an estimated $251K sold.

Prelude Capital Management first reported a position in BIOSU in Q4 2021 and held it in 4 quarters. The position peaked at $252K in Q2 2022. 11 funds tracked by Wall St. Rank hold BIOSU as of Q4 2022.

Prelude Capital Management reported no remaining BioPlus Acquisition Corp. Unit position as of Q4 2022 after selling out during the quarter.
Prelude Capital Management sold 25,000 BioPlus Acquisition Corp. Unit shares in Q4 2022, an estimated $251K.
Prelude Capital Management first reported a position in BioPlus Acquisition Corp. Unit in Q4 2021 and held it in 4 quarters.
Prelude Capital Management's BioPlus Acquisition Corp. Unit position peaked at $252K in Q2 2022.
11 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Unit as of Q4 2022.

Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.